1995 Volume 35 Issue 2 Pages 157-162
In a phase II study, we investigated the efficacy and safety of a cisplatin-carboplatin combination therapy regimen in previously untreated non-small cell lung cancer patients. Of the 56 patients enrolled in the study, 55 met the treatment criteria; 30 had adenocarcinoma, 20 squamous cell carcinoma, and 5 large cell carcinoma. Based on the results of an earlier phase I study, cisplatin 80mg/m2 and carboplatin 350mg/m2 were used, and 8, 33, and 14 patients received 1, 2, and 3 treatment courses, respectively. The antitumor effect was determined and 1 patient showed a complete response, 15 a partial response, 31 no change, 5 progressive disease, and 3 not evaluated; the over all efficacy rate was 30.8%. Mean survival time was 81 weeks for patients with stage III A cancer, 37 weeks for those with stage III B and IV cancer, and 42 weeks overall. Adverse reactions inclued leukopenia of grade ≥ 3 (20% of patients), thrombocytopenia (63.6%), and anemia (50%); gastrointestinal toxicity was also high, although there were no treatment related deaths. Therefore the treatment was considered tolerable. We concluded that this cisplatin-carboplatin chemotherapy regimen is effective for the treatment of non-small cell lung cancer.
